{"filing":{"accession_number":"0001437749-26-031199","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"mbrx20260924_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/mbrx20260924_8k.htm"},"events":[{"id":35068,"run_id":32295,"accession_number":"0001437749-26-031199","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This disclosure announces new preclinical research findings on Annamycin's mechanism of action in pancreatic cancer, presented at a scientific conference. While the data is preclinical and not part of the company's lead clinical program (MIRACLE trial), it represents a material operational/scientific development that could inform future development strategy and combination approaches. The finding that Annamycin's activity is \"partially mediated by CD8+ T cell cytotoxicity\" expands the potential therapeutic applications and mechanisms, which would be relevant to a reasonable investor assessing the company's pipeline and strategic direction.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":[{"id":38997,"accession_number":"0001437749-26-031199","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces new preclinical research findings on Annamycin's mechanism of action in pancreatic cancer, presented at a scientific conference. While the data is preclinical and not part of the company's lead clinical program (MIRACLE trial), it represents a material operational/scientific development that could inform future development strategy and combination approaches. The finding that Annamycin's activity is \"partially mediated by CD8+ T cell cytotoxicity\" expands the potential therapeutic applications and mechanisms, which would be relevant to a reasonable investor assessing the company's pipeline and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T17:06:48.279444+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38997,"accession_number":"0001437749-26-031199","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces new preclinical research findings on Annamycin's mechanism of action in pancreatic cancer, presented at a scientific conference. While the data is preclinical and not part of the company's lead clinical program (MIRACLE trial), it represents a material operational/scientific development that could inform future development strategy and combination approaches. The finding that Annamycin's activity is \"partially mediated by CD8+ T cell cytotoxicity\" expands the potential therapeutic applications and mechanisms, which would be relevant to a reasonable investor assessing the company's pipeline and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T17:06:48.279444+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-25"}]}